- Datum05.06.2025
- Uhrzeit08:55 - 18:30 Uhr
- Veranstalter
stock3
stock3
Moderator
Hansoh Pharmaceutical Group Co Aktie
Verkaufen
Kaufen
Hansoh Pharmaceutical Group Co Chart
Hansoh Pharmaceutical Group Co Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (L&S)
0,00 %
Intraday
0,00 %
1 Woche
3,65 %
1 Monat
35,24 %
Seit Jahresbeginn
52,69 %
1 Jahr
95,86 %
3 Jahre
Passender Service zu Hansoh Pharmaceutical Group Co
Webinar zu Hansoh Pharmaceutical Group Co
Kursinformationen (L&S)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)1,810-3,000
- Jahrestief / Hoch (€)1,950-3,000
- Schlusskurs (Vortag)
- Eröffnungskurs
Wichtigste Eigenschaften
Dividenden von Hansoh Pharmaceutical Group Co
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| - | 2027 (e) | ||
| - | 2026 (e) | ||
| - | 2025 (e) | ||
| 20.09.2024 | 2024 | 0,201 $ | 1,00 % |
| 03.07.2025 | 2024 | 0,1353 $ | 0,53 % |
| 15.09.2023 | 2023 | 0,0707 $ | 0,74 % |
| 19.06.2024 | 2023 | 0,1422 $ | 0,82 % |
| 08.09.2022 | 2022 | 0,05 $ | 0,37 % |
| 05.06.2023 | 2022 | 0,05 $ | 0,39 % |
| 16.06.2022 | 2021 | 0,09 $ | 0,70 % |
| 07.06.2021 | 2020 | 0,0771 $ | 0,24 % |
Termine von Hansoh Pharmaceutical Group Co
- Aug27Hansoh Pharmaceutical Group CoQ2 2025 Earnings Release
- Mär31Hansoh Pharmaceutical Group CoQ4 2025 Earnings Release
- Sep2Hansoh Pharmaceutical Group CoQ2 2026 Earnings Release
Beschreibung
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
